<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased understanding of the molecular processes associated with the <z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence linked to <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> may be beneficial for early <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> detection and refined diagnosis as well as for improved prognostication </plain></SENT>
<SENT sid="1" pm="."><plain>We applied immunohistochemical staining for the markers Ki-67, p53, beta-catenin and E-cadherin in order to evaluate their prognostic importance in 59 <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>-associated <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Reduced or absent membranous E-cadherin staining was identified in 75% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and predicted poor prognosis in manova (hazard ratio [HR] 3.3, P = 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>The small subset of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with low levels (&lt; 10%) of Ki-67 staining showed a worse prognosis (HR 3.2, P &lt; 0.01), whereas immunostaining for p53 and beta-catenin showed no correlation with prognosis </plain></SENT>
<SENT sid="4" pm="."><plain>Deranged cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> has been demonstrated to be an early event in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="5" pm="."><plain>The down-regulation of E-cadherin and its prognostic importance indicate that cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> may be a prime area for targeted therapies in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>